1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,099 | 0,123 | 11:46 | |
| 0,102 | 0,121 | 10:48 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 10:02 | Brii Biosciences H1 Loss Narrows, Stock Up | 2 | RTTNews | ||
| 03:17 | BRII-B 1H26 Loss Narrows to RMB101M, No Interim Dividend | 1 | AASTOCKS | ||
| 01:10 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results | 66 | PR Newswire | Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026
Emerging Discovery Programs Build Momentum
BRII-5395... ► Artikel lesen | |
| 01:00 | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 07.08. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.07. | Brii Bio reports mixed results from hepatitis B studies | 3 | Investing.com | ||
| 03.07. | Brii Biosciences Limited: Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B | 124 | PR Newswire | End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses... ► Artikel lesen | |
| 03.07. | BRII-B (02137): INSIDE INFORMATION ANNOUNCES TOPLINE END-OF-TREATMENT DATA FROM PHASE 2B ENRICH AND ENHANCE STUDIES FOR THE TREATMENT OF CHRONIC HEPATITIS ... | 1 | HKEx | ||
| 17.06. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT SHARE BUY-BACK PROGRAMME | - | HKEx | ||
| 16.06. | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2026 | - | HKEx | ||
| 22.05. | BRII-B (02137): INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS | 3 | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 23.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT ... | - | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ANNUAL REPORT | - | HKEx | ||
| 16.04. | BRII-B (02137): INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS | 2 | HKEx | ||
| 19.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results | 696 | PR Newswire | Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts
Increasing Discovery Efforts to Drive Long-term Value Creation
Strong Cash Position Supporting Strategic... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 182,18 | -0,82 % | Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? | ||
| ILLUMINA | 182,28 | -0,20 % | ILLUMINA, INC. - 8-K, Current Report | ||
| NANOREPRO | 1,910 | +1,33 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
18.08.2026 / 07:30... ► Artikel lesen | |
| CYTODYN | 0,200 | +17,65 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| IMMUNIC | 13,505 | -1,60 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11.08.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 21,820 | +0,18 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| GENPREX | 3,990 | +1,01 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| PERSONALIS | 14,100 | -2,56 % | XFRA 04X: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VITROLIFE | 8,315 | +0,54 % | Vitrolife AB: Vitrolife Group appoints Erin Schardt Senior Vice President and General Manager, Americas. She will join the Executive Management Team. | Vitrolife Group today announced the appointment of Erin Schardt as Senior Vice President and General Manager, Americas, effective immediately. In this expanded role, Erin will assume responsibility... ► Artikel lesen | |
| PLURI | 4,660 | -100,00 % | Pluri Inc. - 8-K, Current Report | ||
| LEGEND BIOTECH | 18,100 | -0,55 % | Legend Biotech Corp - 6-K, Report of foreign issuer | ||
| ENVERIC BIOSCIENCES | 1,380 | -0,72 % | Enveric Biosciences GAAP EPS of -$0.76 | ||
| ENANTA | 11,000 | -0,90 % | Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus | MAVIRET (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV... ► Artikel lesen | |
| NATURAL ALTERNATIVES INTERNATIONAL | 1,800 | 0,00 % | Natural Alternatives International Inc: Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results | CARLSBAD, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements... ► Artikel lesen | |
| MONOPAR THERAPEUTICS | 92,90 | -9,45 % | Monopar Therapeutics Inc.: Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting 2026 | WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen |
BRII BIOSCIENCES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,118 Euro und damit +9,26 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.